Department of Internal Medicine, Tampere University Hospital, Box 2000, FI-33521 Tampere, Finland.
J Infect. 2011 Dec;63(6):407-19. doi: 10.1016/j.jinf.2011.08.004. Epub 2011 Aug 9.
Bacteremia and sepsis are major health concerns. Despite intensive research, there are only a limited number of successful treatment options, and it is difficult to see the forest for the trees when considering the pathogenesis of this condition. Studies in the last decade have shown that a major pathophysiologic event in sepsis is the progression from proinflammation to an immunosuppressive state. However, recent genome-based data indicate that sepsis-related inflammatory responses are highly variable, which calls in question the classic two-phase model of sepsis. Adequate and timely antimicrobial treatment is a cornerstone for survival in patients with bacteremia and sepsis. However, microbial resistance has emerged as an increasing challenge for clinicians and with an increasing number of resistant pathogens causing infections, selection of empiric antimicrobial treatment has become difficult. Treatment options currently under way are targeted to enhance immune responses, rebalance the regulation of the dysregulated immune system, remove endotoxin and block/inhibit apoptosis.
菌血症和败血症是主要的健康问题。尽管进行了深入的研究,但成功的治疗选择仍然有限,并且在考虑这种疾病的发病机制时,很难一叶障目。过去十年的研究表明,败血症中的一个主要病理生理事件是从促炎状态进展到免疫抑制状态。然而,最近基于基因组的研究数据表明,与败血症相关的炎症反应具有高度的可变性,这对败血症的经典两阶段模型提出了质疑。在菌血症和败血症患者中,及时和充分的抗菌治疗是生存的基石。然而,微生物耐药性已经成为临床医生面临的一个日益严峻的挑战,而且越来越多的耐药病原体引起感染,使得经验性抗菌治疗的选择变得困难。目前正在进行的治疗选择旨在增强免疫反应、重新平衡失调免疫系统的调节、清除内毒素和阻断/抑制细胞凋亡。